Sanofi lifts earnings view as Regeneron stake sale boosts Q2

The French drugmaker said it was now targeting earnings per share growth of 6-7% this year, up from 5%.
The company, which is working on two vaccines aimed at preventing COVID-19, also said it had struck a deal to supply up to 60 million doses of a potential vaccine being developed with GlaxoSmithKline to Britain.